Novo Nordisk Financial Statements
Novo Nordisk Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | December |
© 2009 Morningstar, Inc. Financial Data provided by
Novo Nordisk Income Statement
| 2008 | 2007 | 2006 | |
|---|---|---|---|
| Revenue ($ mil.) | 8,627.7 | 8,257.4 | 6,853.6 |
| Gross Profit ($ mil.) | 6,713.1 | 6,324.3 | 5,158.1 |
| Operating Income ($ mil.) | 2,533.4 | 2,265.8 | 1,731.9 |
| Total Net Income ($ mil.) | 1,826.8 | 1,682.2 | 1,141.4 |
| Diluted EPS (Net Income) | 2.94 | 2.64 | 1.77 |
Novo Nordisk Quarterly Statements
| Quarter Ending Jun 09* | Quarter Ending Dec 08 | Quarter Ending Sep 08 | |
|---|---|---|---|
| Revenue ($ mil.) | 2,452.0 | 2,383.2 | 2,171.6 |
| Gross Profit ($ mil.) | 1,959.7 | 1,902.9 | 1,668.4 |
| Operating Income ($ mil.) | 800.6 | 624.3 | 689.8 |
| Total Net Income ($ mil.) | 564.1 | 441.3 | 514.4 |
| Diluted EPS (Net Income) | 0.93 | 0.72 | 0.83 |
- * Irregular reporting interval
Novo Nordisk Stock Quote & Chart
11/06/09 16:01:41 EST •
NYSE •
64.23
•
 -0.3400
•
-0.5266 %
|
|---|
|
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
|
Novo Nordisk Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 4.00 | 16.45 | 7.01 |
| Price/Earnings Ratio | 18.45 | 384.62 | 25.51 |
| Price/Book Ratio | 5.98 | 3.53 | 6.74 |
| Price/Cash Flow Ratio | 14.45 | 80.00 | 43.48 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed Novo Nordisk Financial Ratios
Novo Nordisk Competitive Intelligence
| Eli Lilly | Pfizer | Sanofi-Aventis | |
|---|---|---|---|
| Annual Sales ($ mil.) | 20,378.0 | 48,296.0 | 40,057.0 |
| Employees | 40,500 | 81,800 | 98,213 |
| Market Cap ($ mil.) | 39,641.3 | 136,859.3 | 96,562.0 |
Competitive Landscape
